BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
25
Mechanism of Action
VEGFR2 Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Receptor 2 Antagonist
Indications (14)
metastaticgastricgastro-esophageal junction (GEJ) adenocarcinoma with disease progression onafter prior fluoropyrimidine-platinum-containing chemotherapyafter platinum-based chemotherapyafter prior therapy with bevacizumaboxaliplatina fluoropyrimidinelung cancercolorectal cancerGastric Cancerlymphomaa single agent or
Clinical Trials (5)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Started Apr 2024
168 enrolled
Gastroesophageal Adenocarcinoma
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Started Oct 2023
37 enrolled
Recurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Carcinoma+3 more
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Started Aug 2023
56 enrolled
Non Small Cell Lung CancerMetastaticRecurrent
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Started Mar 2023
838 enrolled
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Started Nov 2021
35 enrolled
Adenocarcinoma GastricGastrooesophageal Cancer